DiaMedica Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update May 9, 2024
02 Maio 2024 - 9:55AM
Business Wire
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage
biopharmaceutical company currently focused on developing
recombinant KLK1 (DM199) for the treatment of acute ischemic
stroke, announced today that its first quarter 2024 financial
results will be released after the markets close on Wednesday, May
8th. DiaMedica will host a live conference call on Thursday, May
9th at 7:00 AM Central Time to provide a business update and
discuss financial results.
Conference Call details:
Date:
Thursday, May 9, 2023
Time:
7:00 AM CT / 8:00 AM ET
Web access:
https://app.webinar.net/jDdlnVm9Ewq
Dial In:
(646) 357-8785
Conference ID:
07657
Interested parties may access the conference call by dialing in
or listening to the simultaneous webcast. Listeners should log on
to the website or dial in 15 minutes prior to the call. The webcast
will remain available for playback on our website, under investor
relations - events and presentations, following the earnings call
and for 12 months thereafter. A telephonic replay of the conference
call will be available until May 16, 2024, by dialing (888)
660-6345 (US Toll Free) and entering the replay passcode:
07657#.
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc. is a clinical stage
biopharmaceutical company committed to improving the lives of
people suffering from serious diseases with a focus on acute
ischemic stroke. DiaMedica’s lead candidate DM199 (rinvecalinase
alfa) is the first pharmaceutically active recombinant (synthetic)
form of the KLK1 protein, an established therapeutic modality in
Asia for the treatment of acute ischemic stroke and other vascular
diseases. For more information visit the Company’s website at
www.diamedica.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240502797716/en/
Scott Kellen Chief Financial Officer Phone: (763) 496-5118
skellen@diamedica.com Paul Papi Corporate Communications Phone:
617-899-5941 ppapi@diamedica.com
DiaMedica Therapeutics (NASDAQ:DMAC)
Gráfico Histórico do Ativo
De Dez 2024 até Jan 2025
DiaMedica Therapeutics (NASDAQ:DMAC)
Gráfico Histórico do Ativo
De Jan 2024 até Jan 2025
